DESTINY-Gastric02 phase 2 trial results : Enhertu shows clinically meaningful and durable tumor response

AstraZeneca said that Enhertu (trastuzumab deruxtecan) has shown clinically meaningful and durable response in the DESTINY-Gastric02 phase 2 trial featuring patients having HER2-positive advanced gastric ... Read More